Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000886987
Ethics application status
Approved
Date submitted
16/08/2011
Date registered
19/08/2011
Date last updated
19/08/2011
Type of registration
Retrospectively registered
Titles & IDs
Public title
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance
Query!
Scientific title
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance
Query!
Secondary ID [1]
262845
0
Nil
Query!
Universal Trial Number (UTN)
-
Query!
Trial acronym
-
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
polycystic ovary syndrome
270567
0
Query!
hyperlipidemia and impaired glucose tolerance
270568
0
Query!
Condition category
Condition code
Metabolic and Endocrine
270736
270736
0
0
Query!
Metabolic disorders
Query!
Blood
270750
270750
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Group MR : Lifestyle intervention ( 1 hour sessions / 2 times a week moderately physical activity and exercise, indivudial dietary modification monitoring by a dietitian ), plus metformin (2000mg/day, peroral) plus rosuvastatin therapies (10 mg/day rosuvastatin, per oral, n= 18) for 12 weeks.
Query!
Intervention code [1]
269201
0
Treatment: Drugs
Query!
Intervention code [2]
269212
0
Lifestyle
Query!
Comparator / control treatment
Group M: Lifestyle intervention ( 1 hour sessions / 2 times a week , moderately physical activity and exercise, indivudial dietary modification monitoring by a dietitian) plus metformin therapy (2000mg/day, per oral, n= 20) for 12 weeks
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
269435
0
Total and free testosterone, insulin, glucose and hs-CRP levels. Blood samples were obtained before and after treatment. They assesed with biochemical tests.
Query!
Assessment method [1]
269435
0
Query!
Timepoint [1]
269435
0
before treatment and after 12 weeks of treatment
Query!
Secondary outcome [1]
287641
0
Nil
Query!
Assessment method [1]
287641
0
Query!
Timepoint [1]
287641
0
Nil
Query!
Eligibility
Key inclusion criteria
PCOS was defined according to Rotterdam European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine(ASRM) consensus workshop. All patients had at least two of the following three criteria: chronic anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovaries on ultrasound (USG).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
The patients who had liver and kidney diseases and using drugs affecting insulin sensitivity and lipid profile and oral contraceptives within the last six months were excluded from the study. Patients with Cushing's syndrome, hyperprolactinemia, diabetes mellitus, thyroid disease, congenital adrenal hyperplasia and androgen-secreting tumors, insufficient LH syndrome and other endocrinopathies were also excluded from the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients were assigned to receive lifestyle-intervention (diet and exercise) and metformin (2000mg/day, n= 20, M group) therapy or lifestyle-intervention, metformin plus rosuvastatin therapies (2000mg/day metformin and 10 mg/day rosuvastatin, n= 18, MR group) for 12 weeks.
For statin administration, newly diagnosed PCOS patients with hyperlipidemia and IGT were selected among PCOS patients at high risk for cardiovascular disease. PCOS patients with a LDL-cholesterol level>130 mg/dL and triglyceride (TG) level>150 mg/dL were considered as hyperlipidemic patients. Among hyperlipidemic patients, 18 patients with a LDL-cholesterol level> 160 mg/dL were scheduled to receive additional rosuvastatin therapy. Allocation is not concealed.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation used according to their lipid profile. PCOS patients with a LDL-cholesterol level>130 mg/dL and triglyceride (TG) level>150 mg/dL were considered as hyperlipidemic patients. Among hyperlipidemic patients, 18 patients with a LDL-cholesterol level> 160 mg/dL were scheduled to receive additional rosuvastatin therapy. 20 patients received only metformin therapy.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Nil
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
5/05/2009
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
3790
0
Turkey
Query!
State/province [1]
3790
0
Istanbul
Query!
Funding & Sponsors
Funding source category [1]
269666
0
University
Query!
Name [1]
269666
0
Istanbul University
Query!
Address [1]
269666
0
Istanbul University
Cerrahpasa Tip Fakultesi , Ic Hastaliklari Anabilim Dali
Endokrinoloji-Metabolizma ve Diyabet Bilim Dali , 34303
Cerrahpasa , Istanbul
Query!
Country [1]
269666
0
Turkey
Query!
Primary sponsor type
Individual
Query!
Name
Ozlem Celik
Query!
Address
Istanbul University
Cerrahpasa Tip Fakultesi , Ic Hastaliklari Anabilim Dali
Endokrinoloji-Metabolizma ve Diyabet Bilim Dali , 34303
Cerrahpasa , Istanbul ,
Query!
Country
Turkey
Query!
Secondary sponsor category [1]
266703
0
None
Query!
Name [1]
266703
0
Query!
Address [1]
266703
0
Query!
Country [1]
266703
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
269620
0
Istanbul University, Cerrahpasa Medical School
Query!
Ethics committee address [1]
269620
0
Istanbul University, Cerrahpasa Medical School,
Cerrahpasa Tip Fakultesi , Ic Hastaliklari Anabilim Dali
Endokrinoloji-Metabolizma ve Diyabet Bilim Dali , 34303
Kocamustafapasa, Istanbul ,
Query!
Ethics committee country [1]
269620
0
Turkey
Query!
Date submitted for ethics approval [1]
269620
0
22/04/2009
Query!
Approval date [1]
269620
0
05/05/2009
Query!
Ethics approval number [1]
269620
0
4004
Query!
Summary
Brief summary
Objective: We aimed to compare the effects of metformin and metformin plus rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (PCOS).
Design: A prospective, randomized study.
Setting: University hospital.
Patients: Thirty-eight PCOS patients with hyperlipidemia and impaired glucose tolerance (IGT) were included in the study.
Interventions: Patients were assigned to receive lifestyle intervention and metformin (2000mg/day, n= 20, M group) therapy or lifestyle intervention, metformin (2000mg/day) plus rosuvastatin therapies (10 mg/day rosuvastatin, n= 18, MR group) for 12 weeks. Blood samples were obtained before and after treatment.
Main Outcome Measures: Total and free testosterone, insulin, glucose and hs-CRP levels. Results: After 12 weeks of treatment body mass index (BMI), insulin and glucose levels, HOMA-IR had similar decreaments in both groups (p= 0.5, p=0.97, p=0.74, p=0.94), whereas there was a greater decline of the total and free testosterone levels in MR group (p< 0.001, p= 0.004). DHEAS levels did not change in M group however significantly decreased in MR group after treatment (p=0.8, p=0.002). As expected hsCRP, triglyceride, total and LDL- cholesterol levels decreased more in MR group.
Conclusion: Metformin and rosuvastatin combination therapy was proved to have more favorable effect on hyperandrogenism. Therefore statin therapy in PCOS patients with hyperlipidemia and higher cardiovascular risk can render hyperandrogenism treatment more successful.
Query!
Trial website
-
Query!
Trial related presentations / publications
-
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33025
0
Query!
Address
33025
0
Query!
Country
33025
0
Query!
Phone
33025
0
Query!
Fax
33025
0
Query!
Email
33025
0
Query!
Contact person for public queries
Name
16272
0
Ozlem Celik
Query!
Address
16272
0
Cerrahpasa Tip Fakultesi , Ic Hastaliklari Anabilim Dali
Endokrinoloji-Metabolizma ve Diyabet Bilim Dali , 34303
Cerrahpasa , Istanbul ,
Query!
Country
16272
0
Turkey
Query!
Phone
16272
0
90 532 7421609
Query!
Fax
16272
0
90 212 233 38 06
Query!
Email
16272
0
[email protected]
Query!
Contact person for scientific queries
Name
7200
0
Ozlem Celik
Query!
Address
7200
0
Cerrahpasa Tip Fakultesi , Ic Hastaliklari Anabilim Dali
Endokrinoloji-Metabolizma ve Diyabet Bilim Dali , 34303
Cerrahpasa , Istanbul ,
Query!
Country
7200
0
Turkey
Query!
Phone
7200
0
90 532 7421609
Query!
Fax
7200
0
90 212 233 38 06
Query!
Email
7200
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF